TIMOPHEI NIZHEGORODTSEV: WHEN PHARMACEUTICAL COMPANIES MANIPULATE OPINIONS OF MEDICAL WORKERS AND PATIENTS, THE GOAL IS ALWAYS OVERPRICING MEDICINE

09-06-2018 | 09:56

A representative of FAS specialized Department discussed specifics of competition on the market of pharmaceuticals

 

Head of FAS Department for Control over Social Sphere and Trade, Timophei Nizhegorodtsev took part in the XII All-Russian Forum “Health of the nation – the basis for prosperity of Russia”. Speaking at the session devoted to medicine circulation under the “Seven nosologies” programme”, he highlighted specifics of competition on the market of pharmaceuticals.

 

Price reduction is one of the benefits associated with competition. Practice shows, however, that this hard and fast rule is not always present on the pharmaceuticals market. Pharmaceuticals demand is not elastic and to a great extent it does not depend on consumers but on the opinions of health system representatives and patient communities, which are not always corroborated. As a result, although several same medicine from different manufacturers may be present on retail market at overrated prices, their prices are not going down. FAS has repeatedly faced it in its investigations”, reported Timophei Nizhegorodtsev.

 

According to Head of FAS specialized Department, not everybody is happy with fair competition. Pharmaceutical companies are attempting to manipulate registration data and opinions of medical and patient communities. Interaction between pharmaceutical companies and communities of patients and medical workers should be maximum transparent and it must be regulated.

 

Representatives of the health care system, patients organizations must report about a conflict of interests if it concerns assessments of a medicinal drug competing with a drug manufactured by a pharmaceutical companies that finance activities of those speakers. Also, all discussion participants should refer to adequate information sources. Competition on the market of medicine must be fair and transparent. When pharmaceutical companies manipulate opinions of medical workers and patients, the goal is always overpricing, and it is a serious problem, so FAS, in particular, must focus on solving it”, emphasized Timophei Nizhegorodtsev.

 



Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do General Information Mission, Goals, Values Priority Setting Institutional Memory Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings GCR Using our website International Cooperation Treaties & Agreements International Working Groups Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Concept Note Meetings OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 OECD meetings 2018 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 13th session IGE UNCTAD Resolution Russian contributions 14th session IGE UNCTAD Resolution Russian contributions 15th session IGE UNCTAD 16th session IGE UNCTAD 17th session IGE UNCTAD EEU Model Law on Competition ICN BRICS WG (Markets of Social Importance) EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Document Library Legislation Reports & Analytics Cases & decisions Contacts Give feedback Contact us Links Authorities Worldwide